The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Also received tentative approval for 137 mg
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Subscribe To Our Newsletter & Stay Updated
